Marginal keratitis associated with administration of filgrastim and sargramostim in a healthy peripheral blood progenitor cell donor.
OBJECTIVE
To describe a 61-year-old healthy peripheral blood progenitor cell (PBPC) donor who developed marginal keratitis and mild uveitis on the third day after receiving daily recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF; sargramostim) to mobilize PBPCs for allogeneic transplantation.


METHODS
Interventional case report.


RESULTS
The keratitis was treated with topical administration of 1% prednisolone acetate solution and resolved within 24 hours. The topical steroid dose was tapered and ultimately discontinued without recurrence of keratitis.


CONCLUSIONS
Healthy PBPC donors receiving rhG-CSF or rhGM-CSF should be monitored for ocular complications, particularly marginal keratitis and uveitis.
Ophthalmology Section, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, U.S.A. besmaeli@mdanderson.org
Bita
B
Esmaeli
M Amir
MA
Ahmadi
Stella
S
Kim
Hillary
H
Onan
Martin
M
Korbling
Paolo
P
Anderlini
D000208:Acute Disease; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects*; D006412:Hematopoietic Stem Cells; D006801:Humans; D007634:Keratitis / Q000139:chemically induced*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D014605:Uveitis / Q000139:chemically induced*
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim